ACAD Jan 2025 42.000 call
| Previous Close | 2.3000 |
| Open | 2.3000 |
| Bid | 1.1000 |
| Ask | 1.5000 |
| Strike | 42.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 2.3000 - 2.3000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 11 |
Insider MonkeyWhy Is ACADIA Pharmaceuticals Inc (ACAD) One of the Best Debt Free Halal Stocks According to Hedge Funds?
We recently compiled the list of the 7 Best Halal Stocks To Buy Now (Debt Free). In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against the other debt free halal stocks. Halal Investing: Debt-Free Stocks, Islamic Funds, and Shariah-Compliant Indices Islamic equity investing, also known as […]
Business WireAcadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
SAN DIEGO, June 18, 2024--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE™ (trofinetide).
Simply Wall St.It's Probably Less Likely That ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Will See A Huge Pay Rise This Year
Key Insights ACADIA Pharmaceuticals' Annual General Meeting to take place on 29th of May Total pay for CEO Steve Davis...
